http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2338561-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2817954cd008bcd609a4c4eb49050be |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57509 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 1999-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af6a5e04b5e52d6135cd661818535fb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12db1e8d469dfe4867bcb9ea3a1d7a74 |
| publicationDate | 2000-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2338561-A1 |
| titleOfInvention | Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2) |
| abstract | The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N- terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Recepto r, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid . Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vecto r of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed the antagonist of t he present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a ki t comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparati on of a pharmaceutical composition for preventing and/or treating a Corticotrop in- Releasing Factor Receptor, type 2 (CRFR2)-associated disease. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1379873-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7572768-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1379873-A2 |
| priorityDate | 1998-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.